Sitagliptin for the prevention and treatment of perioperative hyperglycaemia in patients with type 2 diabetes undergoing cardiac surgery: A randomized controlled trial.
Saumeth CardonaKaterina TsegkaFrancisco J PasquelSol JacobsMichael HalkosW Brent KeelingGeorgia M DavisMaya FayfmanBonnie AlburyMaria A UrrutiaRodolfo J GalindoAlexandra L MigdalSteven MacheersRobert A GuytonPriyathama VellankiLimin PengGuillermo E UmpierrezPublished in: Diabetes, obesity & metabolism (2020)
The administration of sitagliptin prior to surgery and during the hospital stay did not prevent perioperative hyperglycaemia or complications after CABG. Sitagliptin therapy was associated with lower mean daily insulin requirements after transition to regular wards.
Keyphrases
- cardiac surgery
- acute kidney injury
- coronary artery bypass
- minimally invasive
- type diabetes
- patients undergoing
- healthcare
- coronary artery bypass grafting
- acute care
- glycemic control
- replacement therapy
- coronary artery disease
- percutaneous coronary intervention
- skeletal muscle
- insulin resistance
- acute coronary syndrome
- smoking cessation